The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache

Study Overview
=================
Brief Summary
-----------------
To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with a phosphodiesterase inhibitor (cilostazol). If the headache responds to sumatriptan, the model can be used to test new drug candidates.

Detailed Description
-----------------
There remains a great need for more effective anti-migraine drugs with fewer side effects. Human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. The investigators' group has shown that Cilostazol, a phosphodiesterase inhibitor induce headache/migraine in both healthy volunteers and in patients with migraine without aura (MO). To validate this model, the headache must respond to specific migraine treatment with sumatriptan. Hypothesis: Cilostazol induces a migraine-like headache in both healthy subjects and in MO-patients and induced headache responds to a specific anti migraine drug; sumatriptan. Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs.

Official Title
-----------------
The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: Cilostazol
* Drug: Sumatriptan
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Healthy: Healthy subjects of both sexes Age 18-70 years Weight 50-90 kg. Females were requested to use effective contraception. Migraine patients: Migraine patients who meet IHS criteria for migraine with or without aura of both sexes 18-70 years 45-95 kg. Exclusion Criteria: Healthy: Any type of headache (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives). Migraine patients: Any other type of headache then migraine without aura (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Sumatriptan<br>headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg | Drug: Cilostazol<br>* Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan<br>* Other names: Pletal;Drug: Sumatriptan<br>* Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan<br>* Other names: Imigran;|
| Placebo Comparator: Placebo<br>headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo | Drug: Cilostazol<br>* Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan<br>* Other names: Pletal;Drug: Placebo<br>* Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in median headache score 2 hours after sumatriptan/placebo | The investigators will assess the outcome measures 1 year after the beginning of the study | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the headache score curve | The investigators will assess the outcome measures 1 year after the beginning of the study | 12 hours |